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OBJECTIVES This study was designed to determine whether antisense oligodeoxynucleotides (ODN)
directed against the nuclear proto-oncogene c-myc could inhibit restenosis when given by
local delivery immediately after coronary stent implantation.
BACKGROUND Failure of conventional pharmacologic therapies to reduce the incidence of coronary
restenosis after percutaneous revascularization techniques has prompted interest in the use of
agents that target intracellular central regulatory mechanisms.
METHODS Eighty-five patients were randomly assigned to receive either 10 mg of phosphorothioate-
modified 15-mer antisense ODN or saline vehicle by intracoronary local delivery after
coronary stent implantation. The primary end point was percent neointimal volume
obstruction measured by computerized analysis of electrocardiogram-gated intravascular
ultrasound (IVUS) at six-month follow-up. Secondary end points included clinical outcome
and quantitative coronary angiography analysis.
RESULTS Analysis of follow-up IVUS data was performed on 77 patients. In-stent volume obstruction
was similar between groups (44  16% and 46  14%, placebo vs. ODN; p  0.57; 95%
confidence interval: 1.13 to 0.85). Minimum luminal diameter increased from 0.84  0.36
and 0.90  0.45 (p  0.55) to 2.70  0.37 and 2.80  0.37 (p  0.28) after stent
implantation, which decreased to 1.50  0.61 and 1.50  0.53 (p  0.98) by six months,
yielding similar loss indexes (placebo vs. ODN, respectively). There were no differences in
angiographic restenosis rates (38.5 and 34.2%; p  0.81; placebo vs. ODN) or clinical
outcome.
CONCLUSIONS Treatment with 10 mg of phosphorothioate-modified ODN directed against c-myc does not
reduce neointimal volume obstruction or the angiographic restenosis rate in this patient
population. (J Am Coll Cardiol 2002;39:281–7) © 2002 by the American College of
Cardiology
The superiority of coronary stent implantation over conven-
tional percutaneous transluminal coronary angioplasty for
long-term outcome demonstrated by several randomized
trials has led to the widespread use of coronary stents for the
treatment of coronary artery disease (1–3). However, coro-
nary stenting procedures are plagued by unacceptably high
rates of restenosis, primarily as a result of neointimal
accumulation. A potential approach for the prevention of
the in-stent neointimal proliferative process involves the use
of antisense oligodeoxynucleotides (AS-ODN) therapeuti-
cally targeted to genes believed to be critical for the
pathogenesis of restenosis. Binding of the AS-ODN to its
target messenger RNA (mRNA) results in an interference
with its stability and translation, thereby preventing the
expression of the targeted gene. c-myc, an immediate-early
proto-oncogene that encodes c-Myc has been successfully
targeted with AS-ODNs. c-Myc is a short-lived sequence-
specific DNA binding nuclear phosphoprotein, which is
involved in the transcriptional modulation of a number of
genes involved in the cell cycle.
The purpose of this study was to determine whether
AS-ODN directed against the nuclear proto-oncogene
c-myc could inhibit the development of restenosis in hu-
mans when given by local delivery techniques immediately
after coronary stent implantation.
METHODS
Patient selection. The trial was approved by the Medical
Ethics Committee of the Academic Hospital Dijkzigt
Rotterdam. Informed consent was obtained from each
patient before enrollment.
The criteria for patient enrollment included the follow-
ing: a single symptomatic or ischemia provoking de novo or
restenotic lesion, suitable for stent implantation in a native
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coronary artery. Patients were excluded if they had experi-
enced a myocardial infarction within 15 days of the proce-
dure, impaired left ventricular function (left ventricular
ejection fraction 35%), renal impairment (serum creati-
nine2.0 mg/dl [180 mol/l]), hepatic dysfunction (total
bilirubin 2.0 mg/dl [35 mol/l], alanine aminotransfer-
ase or aspartate aminotransferase 2 the upper limit of
the reference range), an ostial lesion, a total occlusion, a
target artery 2.5 mm or 4.0 mm in diameter or a target
lesion 40 mm in length.
End points. The primary end point was percent in-stent
volume obstruction as measured by intravascular ultrasound
(IVUS) at six months follow-up catheterization. Secondary
angiographic end points included minimum luminal diam-
eter and loss index of the stented segment as measured by
off-line quantitative coronary analysis (QCA) at six-months
follow-up angiography. Secondary clinical end points were
the composite outcome (and each component) of death
(cardiac and noncardiac), myocardial infarction (at least two
of: a history of chest discomfort of at least 30 min duration,
twice the upper limit of normal of creatine kinase [CK]
together with a pathological increase in the MB iso-enzyme
of CK and the development of new and abnormal Q waves)
(4), emergency or elective bypass surgery involving the
previously treated segment and percutaneous revasculariza-
tion of the treated vessel within six months of follow-up.
The feasibility, safety and tolerability of the administration
of LR-3280 within a stented segment using a local delivery
device were also assessed.
Stent implantation. All patients received intra-arterial as-
pirin (250 mg) and heparin (10,000 IU) at the beginning of
the procedure. Intraprocedural supplemental doses of hep-
arin were given in order to maintain an activated clotting
time of more than 300 s. Randomization took place after
successful balloon predilation and the implantation of a
self-expanding coronary Wallstent (Schneider AG, Bu¨lach,
Switzerland). After successful stent deployment, balloon
postdilation to 12 atm was performed using semi- or
noncompliant balloons of sufficient diameter to achieve a
diameter stenosis of 20% as measured by on-line QCA.
The use of IVUS for guidance of stent deployment was left
to the discretion of the treating physician. Although the
intention was to use a single Wallstent for each target
lesion, second stents could be used when clinically indicated.
Antisense oligonucleotides. LR-3280 (Lynx Therapeu-
tics, Hayward, California) is a 15-mer phosphorothioate
oligonucleotide antisense to the 5 translation initiation
region of c-myc mRNA with the sequence 5-
AACGTTGAGGGGCAT-3. It was supplied as a lyoph-
ilized powder and reconstituted with physiologic saline just
before administration. Patients randomized to placebo
treatment received the saline vehicle only. Blinding was
achieved by the use of tamper-proof, foil-covered vials.
Local delivery. All LR-3280 and placebo treatments were
administered in 2.0 ml using the Transport (Scimed, Boston
Scientific Corporation, Minneapolis, Minnesota) local de-
livery catheter, which consists of a dual balloon system with
an inner support balloon and an outer delivery balloon (1 cm
in length). The inner support balloon was inflated to 3 atms.
A total of 10 mg of LR-3280 was delivered to the stented
segment using one, two or three deliveries, depending on
stent length. The duration of each delivery was 1 min and
controlled with a programmable infusion pump.
QCA analysis. Angiographic analysis was performed off-
line at the angiographic core lab (Cardialysis, Rotterdam,
the Netherlands) using the Cardiovascular Angiographic
Analysis System (CASS II, Pie Medical Imaging, Maas-
tricht, The Netherlands) as described elsewhere (1,5–8).
For each patient, three angiograms in multiple projections
were obtained after the intracoronary administration of
0.2 mg of isosorbide dinitrate, pre- and postprocedure and
at six-month follow-up.
IVUS image acquisition and analysis. At six month
follow-up, the stented vessel segments were examined with
a mechanical IVUS system (ClearView console, Cardio-
Vascular Imaging System [CVIS], Sunnyvale, California)
using a sheath-based IVUS catheter incorporating a trans-
ducer rotating at 1,800 rpm (MicroView, CVIS) after the
intracoronary administration of isosorbide dinitrate (0.2 mg
to 0.4 mg). The 30 MHz single-element IVUS transducer
was withdrawn through the sonolucent imaging sheath by
an automated electrocardiogram-triggered pullback device
with a stepping motor (EchoScan, Tomtec, Munich, Ger-
many) at 0.2 mm per step (9). A computer-based contour
detection program, developed at our institute, was used for
the automated three-dimensional analysis of up to 200
IVUS images (10). The feasibility and reproducibility of this
system have been previously validated in vitro and in vivo
(11–13), and the inter- and intraobserver differences in
volumetric measurement (nonstented segments) have been
reported (n  30; r  0.99) (11).
Plasma LR-3280 concentrations. Blood serum concentra-
tions of LR-3280 were measured as part of the safety
assessment of the antisense compound. Blood samples were
collected from the arterial sheath before, immediately after
and at 10 min and 30 min after delivery. Samples were
collected in evacuated tubes containing lithium-heparin and
placed immediately on ice for transport to the analytical
laboratory where the plasma component was separated. The
plasma samples were then stored at 20°C until batch
assayed in a blinded manner at a central laboratory (Schwarz
Pharma, AG, Monheim, Germany) by a competitive hy-
bridization immunoassay (14).
Abbreviations and Acronyms
AS-ODN  antisense oligodeoxyribonucleotide
CK  creatine kinase
IVUS  intravascular ultrasound
mRNA  messenger RNA
ODN  oligodeoxyribonucleotide
QCA  quantitative coronary analysis
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Power calculation and statistical analysis. The size of the
patient group required to test the hypothesis was calculated
based on an expected in-stent neointimal volume as mea-
sured by IVUS of 129 mm3, a value that was determined
from earlier observations at six-month follow-up of patients
who had received the Wallstent (15). To detect a reduction
in neointimal volume of 30% with LR-3280 treatment with
81% power at a two-sided type 1 error rate (alpha) of 0.05,
it was calculated that a total of 70 evaluable patients were
necessary. This assumes that the SD is 50% of the actual
plaque volume in the control group.
Continuous variables are expressed as means  SD and
were compared by the unpaired Student t test. The chi-
square test with Yates’ correction was used to compare
proportions. Discrete variables are expressed as counts and
percentages and were compared in terms of relative risks
with 95% confidence intervals calculated by the formula of
Greenland and Robins (16). All statistical tests were two-
tailed.
RESULTS
Baseline characteristics. Patient flow through the study is
shown in Figure 1. The baseline characteristics of the 85
randomized patients included in the intention-to-treat anal-
ysis are shown in Table 1. Four placebo- and three
antisense-treated patients had the IIb/IIIa platelet receptor
antagonist ReoPro (Eli Lilly Nederland BV, Nieuwegein,
The Netherlands) administered after stent implantation.
Plasma AS-ODN concentrations. All pretreatment blood
samples showed values below the quantification limits for
the assay (10 ng/ml). In addition, random analyses of all
timed blood samples from three patients in the placebo
group were analyzed and were also below the limit of
quantification. The serum concentrations of antisense oli-
gonucleotide in the study patients are shown in Figure 2. At
all time points the serum concentrations were 5 M
(25 g/ml), which is below the level at which nonspecific
effects of phosphorothioate AS-ODNs have been suggested
to occur (17).
Outcome of IVUS analysis. Intravascular ultrasound anal-
ysis data at six-month follow-up were available in 34 (87%)
of the placebo-treated patients and 34 (89%) of the LR-
3280-treated patients. In the remaining patients, IVUS
interrogation was not possible because the degree of intimal
proliferation prevented passage of the IVUS catheter. For
these patients, prospectively defined imputation rules were
employed to estimate the neointimal volume (see Appen-
dix). The in-stent volume obstruction was similar between
the two groups (44  16% and 46  14%; mean  SD,
placebo vs. LR-3280, p  0.57) (Table 2). In addition,
there were no significant differences in lumen area, stent
length, stent volume, lumen volume or in-stent neointimal
volume.
Outcome of angiographic follow-up. Complete six-
month angiographic follow-up data were available for 77
patients. There were no significant differences in the base-
line or follow-up angiographic variables between the two
treatment groups. Minimum luminal diameter increased
from 0.84  0.36 and 0.90  0.45 mm to 2.70  0.37 mm
and 2.80  0.37 mm (mean  SD) immediately after stent
implantation (placebo vs. control, respectively), but by six
months follow-up it had decreased to 1.50  0.61 and
1.50  0.53 (p  0.98), yielding loss indexes that were not
significantly different. The binary restenosis rate (50%
lumen obstruction) at six-month follow-up was likewise
Figure 1. Patient flow in the ITALICS trial.
Table 1. Baseline Clinical and Angiographic Characteristics of
85 Patients Included in the Intention-to-Treat Analysis
According to Treatment Group
Characteristics
Placebo
(n  43)
LR-3280
(n  42)
Age, yrs* 63.0  9.4 58.0  10.0
Male gender, no. (%) 25 (58) 33 (79)
Risk factors, no. (%)
Current smoking 8 (19) 10 (24)
Diabetes mellitus 4 (9) 4 (10)
Hypercholesterolemia 21 (49) 16 (38)
Hypertension 13 (30) 15 (36)
Family history of ischemic heart disease 16 (37) 18 (43)
Previous myocardial infarction, no. (%) 16 (37) 15 (36)
Exertional angina, no. (%)
Class I 0 (0) 1 (2)
Class II 6 (14) 7 (17)
Class III 7 (16) 8 (19)
Class IV 4 (9) 0 (0)
Unstable angina, no. (%)
Class IB 4 (9) 6 (14)
Class IIB 16 (37) 16 (38)
Class IC 2 (5) 0 (0)
Class IIC 3 (7) 4 (10)
Vessel treated, no. (%)
LAD 18 (42) 18 (43)
LCx 6 (14) 6 (14)
RCA 19 (44) 18 (43)
*Expressed as mean  SD.
LAD  left anterior descending coronary artery; LCx  left circumflex coronary
artery; RCA  right coronary artery.
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similar in the two groups (38.5% and 34.2%, placebo versus
LR-3280; p  0.81).
Clinical events. The incidence of major cardiac events pre-
sented as single worst event per patient is shown in Table 3.
There was no significant difference in the event rate between
patients treated with placebo and those treated with LR-3280.
At 210 days, event-free survival by Kaplan-Meier analysis was
72.1% in the placebo group as compared with 71.4% in the
LR-3280-treated group (Fig. 3, p 0.91). The single death in
the placebo-treated group occurred five months after the local
delivery procedure and resulted from a complication of coro-
nary artery bypass grafting.
DISCUSSION
The AS-ODNs directed against c-myc have been the most
extensively studied of the antisense DNA sequences con-
sidered for the prevention of restenosis after coronary
interventions and have been shown to decrease c-Myc
protein expression and inhibit the growth of both rat and
Figure 2. Boxplot of serum concentrations of LR-3280. Arterial blood samples were drawn from 20 patients immediately (time 0) and at 10 min and 30
min after the intracoronary local administration of LR-3280. Bars represent median values, and boxes represent 25th and 75th percentiles. Extreme
(asterisk) and outlying (solid circle) points are shown.
Table 2. Follow-Up Intravascular Ultrasound Results According to Treatment Groups
Placebo LR-3280 p Value
95% Confidence
Interval
Lower Upper
Without imputation
Number of observations 34 34
In-stent neointimal volume, mm3 135  118 143  99 0.76 59.95 43.56
In-stent volume obstruction (%) 40  12 44  10 0.17 9.07 1.52
With imputation
Number of observations 39 38
Mean lumen area, mm3 5.60  2.19 5.46  2.25 0.77 1.13 0.85
Stent length, mm 32  16 30  12 0.62 8.31 4.31
Stent volume, mm3 321  187 316  186 0.91 88.32 78.32
Lumen volume, mm 171  94 172  103 0.98 43.08 45.08
In-stent neointimal volume, mm3 150  120 145  96 0.84 53.48 43.48
In-stent volume obstruction (%) 44  16 46  14 0.57 3.02 7.02
284 Kutryk et al. JACC Vol. 39, No. 2, 2002
Antisense Oligonucleotides for Restenosis Prevention January 16, 2002:281–7
human vascular smooth muscle cells in vitro (18,19) and
prevent restenosis in animal models (20–23). In the present
trial, 10 mg of LR-3280 administered using a local delivery
device immediately after coronary stenting did not lead to a
reduction in the neointimal volume obstruction as measured
by IVUS at six-month follow-up, nor were there any
differences in the angiographic parameters of minimum
luminal diameter, late loss, loss index or binary restenosis
rate at six-month follow-up. The frequency of clinical
events was also similar between the two groups.
Study limitations. There may be several reasons for the
observed lack of effect of the antisense compound. First, the
local concentration of antisense compound achieved may
not have been high enough or maintained long enough to
show a significant effect. The dose of antisense compound
used in this study was chosen based on existing safety and
efficacy data. Using the same antisense compound and a
porous balloon delivery catheter, Shi et al. (23) have shown
that the efficiency of delivery is 1% in a swine coronary
model of vessel injury. In diseased human vessels, the tissue
retention of compound delivered via local intracoronary
administration using a coil balloon has been shown to be
between 1% and 8% (24). It is possible that the use of a
delivery device that better targets the media could have
resulted in higher tissue concentrations of AS-ODNs.
Second, the single administration of AS-ODN employed
in the present trial may not have been effective. It is known
that after acute vessel injury, c-myc expression shows a
biphasic response with early and late expression peaks
(19,25,26). The delivered antisense compound may have
been effective in suppressing early c-Myc protein produc-
tion, but washout and degradation may have resulted in
tissue concentrations too low to suppress expression by the
later peak. Very little is known about the expression of
c-myc expression in stented vessels, and the self-expanding
nature of the stent chosen for use in the present trial with its
persistent radial strain on the vessel wall may have further
confounded the results (15).
Third, it has been shown that the intraluminal delivery of
saline using a local delivery device can exaggerate the intimal
proliferative response (27). It is possible that the use of a
saline vehicle in this trial aggravated the neoproliferative
Table 3. Major Adverse Cardiac Events to 210 Days:
Hierarchical Ranking of Worst Event per Patient (Intention-to-
Treat) According to Treatment Group
Placebo
(n  43)
LR-3280
(n  42)
Death, no. (%) 1 (2) 0
MI, no. (%) 3 (7) 5 (12)
Q-wave, no. (%) 1 (2) 3 (7)
Non–Q-wave, no. (%) 2 (5) 2 (5)
CABG, no. (%) 1 (2) 0
re-PTCA, no. (%) 7 (16) 7 (17)
No adverse event, no. (%) 31 (72) 30 (71)
CABG  coronary artery bypass grafting; MI  myocardial infarction; PTCA 
percutaneous transluminal coronary angioplasty.
Figure 3. Kaplan-Meier survival curves for major cardiac events (death, myocardial infarction, coronary artery bypass surgery and repeat percutaneous
revascularization of the target lesion). p  0.91 determined by the log-rank test. The cluster of events just after 180 days reflects the scheduled follow-up.
Dashed line  placebo group; solid line  LR-3280 group.
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response and masked any beneficial effect of the antisense
compound.
Finally, it must be considered that the target chosen was
not appropriate. Although the c-myc proto-oncogene is
believed to be one of the members of the final common
pathway of cell cycle regulation, it is not the sole controlling
mechanism for neointimalization. It is possible that, with a
combination of antisense ODNs targeting different genes,
inhibition of neointimal formation might be achieved. Proof
of this concept has been shown in an animal model of
vascular injury (28).
Conclusions. The results of this trial indicated that the
administration of 10 mg of AS-ODN directed against
c-myc using the transport local delivery catheter immedi-
ately after implantation of a self-expanding intracoronary
stent was ineffective for the prevention of restenosis mea-
sured at six-month follow-up. There were no adverse effects
to the trial medication or from the method of delivery so
that a safe platform for future studies has been established.
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APPENDIX
Imputation Rules
In situations of total vessel occlusion, the assumption was
that the entire length and volume of the stent was filled with
neointimal tissue. In these cases, a contrast free frame was
analyzed by quantitative coronary analysis (QCA), and
the length and mean area of the stent were determined.
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This analysis was performed in the angiographic view
with the longest stent length. The following regression
equations were generated from the unblinded data com-
paring intravascular ultrasound (IVUS) and QCA deter-
mined variables:
1. IVUS empty stent length  2.06  1.02 (QCA deter-
mined stent length). (r2  0.93)
2. IVUS determined lumen area  1.90  0.85 (QCA
determined lumen area); QCA area was calculated using
 (one-half mean diameter)2. (r2  0.66)
3. Preliminary predicted IVUS lumen volume equation 1
multiplied by equation 2.
4. IVUS lumen volume  4.41  0.96 (preliminary pre-
dicted IVUS lumen volume). r2  0.78
These equations were used to correct for the systematic
difference between IVUS and QCA-determined measure-
ments.
In the case of severely stenotic but nonocclusive lesions,
not only was the volume of the stent calculated, but the
volume of the lumen opacified by contrast was also
analyzed. Stent volumes were determined using regres-
sion equations 1 to 4, and the neointimal volume was
calculated as the difference between the stent and the
luminal volume.
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